Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

根据Catalyst的说法，与其他ANDA申请者的诉讼可能会在2025年第四季度进入专利审判阶段。考虑到30个月的仿制药上市延迟期，这可能会将仿制药竞争推迟到至少2026年5月。管理层讨论表明，与首次申请者达成和解通常会导致与其他申请者迅速达成连续协议。

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Citi强调Firdapse的强劲财务表现，预计该药物到2034年在美国的峰值销售额将超过5.5亿美元。这一预测得到了Catalyst的一贯表现支持，自Firdapse获得FDA批准以来，其收入一直保持着两位数的同比增长。因此，与Teva的交割进一步强化了该药物持续收入增长的潜力，并提升了Catalyst的财务前景。

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

Shares of Catalyst Pharmaceuticals Inc. CPRX slipped 3.27% to $19.53 Tuesday, on what proved to be an all-around rough ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.